Insilico Medicine 29. März 2026 Insilico Medicine Announces Global R&D Collaboration with Lilly - Insilico Medicine
FierceBiotech 23. März 2026 Apogee eczema data drive hype to new peak as threat to Lilly and Sanofi becomes clear
Endpoints News 20. März 2026 UK’s NICE revisits Lilly, Eisai Alzheimer's drugs under new pricing threshold
FierceBiotech 19. März 2026 Lilly's obesity discovery partner Fauna sees weight loss potential in hibernating mammals
FierceBiotech 19. März 2026 Lilly's triple-G bet lowers blood sugar, prompts 16.8% weight loss in phase 3 diabetes trial
Endpoints News 19. März 2026 Updated: Lilly’s triple-G comparable with Mounjaro, first Phase 3 diabetes data suggest
BioPharma Dive 12. März 2026 Lilly warns GLP-1 knockoffs may be ‘dangerous,’ escalating war with compounders
Endpoints News 12. März 2026 Lilly warns of impurity risk in certain compounded forms of Mounjaro and Zepbound
Endpoints News 11. März 2026 Lilly plots GLP-1 pill production boost in China, $500M pledge to South Korea
Pharmaron 11. März 2026 Lilly beefs up oral GLP-1 capacity with $3B manufacturing pledge in China - Fierce Pharma
Endpoints News 6. März 2026 Lilly plucks Flagship, bluebird vet for regenerative medicine unit; Novo's new China president